Skip to Main Content

Paper Details

Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Breast Cancer Res Treat
13
2015
Arimidex, Aromatase, Tamoxifen, Women, aromatase, breast cancer, cardiovascular disease, endometrial cancer, fracture, myocardial infarction, patient, tamoxifen, thromboembolic events, women
Author NameAffiliation
Reina HaqueSouthern California Permanente Medical Group
JoAnn E MansonBrigham and Women's Hospital, Harvard Medical School
  • 1 - 2

Datasets

Release 1.2